Detalles de la búsqueda
1.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
N Engl J Med
; 378(22): 2093-2104, 2018 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29658845
2.
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial.
Eur Respir J
; 56(2)2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32444410
3.
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Lancet Oncol
; 20(2): 239-253, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30660609
4.
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
Br J Cancer
; 120(4): 387-397, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30739911
5.
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Lancet
; 387(10026): 1405-1414, 2016 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26719230
6.
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Lancet
; 387(10026): 1415-1426, 2016 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26777916
7.
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.
Eur Respir J
; 50(2)2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28798090
8.
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.
Eur Respir J
; 50(2)2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28798088
9.
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Lung Cancer
; 190: 107508, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38428265
10.
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 25(3): 233-243.e8, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38105153
11.
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial.
Lung Cancer
; 182: 107287, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37393757
12.
Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.
Clin Lung Cancer
; 24(1): 1-10, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36180314
13.
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
J Clin Oncol
; 41(6): 1200-1212, 2023 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36223558
14.
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
J Immunother Cancer
; 11(2)2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36725084
15.
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
J Thorac Oncol
; 18(1): 79-92, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36049658
16.
Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study).
PLoS One
; 18(9): e0291495, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37708140
17.
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion.
J Thorac Oncol
; 18(5): 576-586, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36646211
18.
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.
Eur J Cancer
; 162: 182-193, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35016032
19.
Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
Lung Cancer
; 167: 98-106, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35183375
20.
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts.
Cancers (Basel)
; 14(24)2022 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36551632